Johnson & Johnson vs Transocean Ltd — how do they compare? Johnson & Johnson trades at $259.44 (market cap $630.94B), while Transocean Ltd trades at $5.79 (market cap $6.39B). The key difference: Johnson & Johnson is far larger — about 98.7× Transocean Ltd's market cap, and Johnson & Johnson pays a 2.05% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| JNJ | RIG | |
|---|---|---|
Market Cap | $630.94B | $6.39B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $7.58 |
52-Week Low | $172.78 | $2.80 |
Enterprise Value | $659.21B | $11.00B |
Dividend Yield | 2.05% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.
JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).
Transocean (RIG) trades at $5.26, up 1.94% with neutral technical signals. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses improving to -$1.7B. Recent Q2 2026 earnings beat expectations with $0.03 EPS, and the company secured a significant $1B+ contract with Equinor, boosting long-term visibility. Analyst sentiment is divided with 39% buy ratings, while institutional activity shows mixed positioning with recent large acquisitions by Elliott Investment Management.
RIG presents a turnaround opportunity with improving operational metrics and contract wins, but significant execution risks remain. The pending Valaris merger could create synergies, though current negative profitability and high debt require careful monitoring. The stock offers speculative upside if operational improvements continue, but investors should weigh the substantial losses against the company's market position and backlog growth.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →